Advanced search
Start date

Multi-User Equipment approved in grant 2013/07600-3: MicroScale Thermophoresis (MST)

Grant number: 16/13884-2
Support Opportunities:Multi-user Equipment Program
Duration: October 01, 2016 - September 30, 2023
Field of knowledge:Biological Sciences - Biophysics - Molecular Biophysics
Principal Investigator:Glaucius Oliva
Grantee:Glaucius Oliva
Host Institution: Instituto de Física de São Carlos (IFSC). Universidade de São Paulo (USP). São Carlos , SP, Brazil
Associated research grant:13/07600-3 - CIBFar - Center for Innovation in Biodiversity and Drug Discovery, AP.CEPID
As informações de acesso ao Equipamento Multiusuário são de responsabilidade do Pesquisador responsável
EMU web page:
Type of equipment:Caracterização e Análises de Amostras - Biomédica - Celular
Caracterização e Análises de Amostras - Proteínas/Ácidos nuclêicos - Eletroforese
Manufacturer: Nanotemper
Model: NanoTemper Monolith NT.115


The Center for Innovation in Biodiversity and Drug Discovery (CIBFar) is a joint initiative resulting from existing collaborative research projects, including the Physics Institute of São Carlos (IFSC) and the School of Pharmaceutical Sciences of Ribeirao Preto at the University of São Paulo (USP), the Institute of Chemistry at the State University of São Paulo (UNESP), the Institute of Chemistry at the State University of Campinas (UNICAMP), and the Department of Chemistry at the Federal University of São Carlos (UFSCar). The major goals of this Center are to perform basic and applied science and to develop technologies, such as in vitro and in vivo biological and pharmacological evaluations, for all areas of biodiversity and drug discovery that rely on state-of-the-art methods in medicinal chemistry, natural products chemistry, synthetic organic chemistry, and molecular and structural biology. Strategic partnerships with the private sector are always sought, particularly with national and international pharmaceutical companies and research institutes within the health sector. The ultimate goals are the development of clinical candidates for tropical infectious diseases, cancer and central nervous system disorders and the development of new synthetic routes to generic drugs. On the educational front, the Center also relies on the considerable experience that has been acquired over the last eleven years from our previous CEPID-FAPESP. Intensive work has been done on outreach programs focused on science education from elementary school to high school. CIBFar has the benefit of joining research groups in a modern multidisciplinary setting while also providing access to a well-established infrastructure with extensive experience in the areas of technical, financial, educational, technological and executive management. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
FROES, THAMIRES QUADROS; GUIDO, RAFAEL V. C.; METWALLY, KAMEL; CASTILHO, MARCELO SANTOS. A novel scaffold to fightPseudomonas aeruginosapyocyanin production: early steps to novel antivirulence drugs. Future Medicinal Chemistry, v. 12, n. 16, . (16/13884-2)
FREIRE, MARJORIE C. L. C.; NOSKE, GABRIELA D.; BITENCOURT, NATALIA V.; SANCHES, PAULO R. S.; SANTOS-FILHO, NORIVAL A.; GAWRILJUK, VICTOR O.; DE SOUZA, EDUARDO P.; NOGUEIRA, VICTOR H. R.; DE GODOY, MARIANA O.; NAKAMURA, ALINE M.; et al. Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors. Molecules, v. 26, n. 16, . (18/17095-8, 20/04602-9, 13/07600-3, 20/05761-3, 20/12519-4, 18/25600-4, 16/19712-9, 16/13884-2, 18/13588-0)

Please report errors in scientific publications list using this form.